top of page


FDA approves Roche's Gazyva as first specifically authorised treatment for primary membranous nephropathy
The FDA has approved Roche's Gazyva for primary membranous nephropathy, establishing the first specifically authorised treatment for the condition after Phase III evidence demonstrated substantially higher complete proteinuria remission rates than tacrolimus.

nuaxia
1 hour ago2 min read


FDA approves Gazyva for idiopathic nephrotic syndrome in patients aged two years and older
The FDA has approved Gazyva for patients aged two years and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission.

nuaxia
Oct 12 min read
bottom of page